Barclays Raises PT on Coach (COH) After Meeting With Management
Tweet
Share
E-mailGet Alerts COH Hot Sheet
Price: $39.90 --0%
Rating Summary:
18 Buy, 20 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 16 | New: 37
Rating Summary:
18 Buy, 20 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 16 | New: 37
Join SI Premium – FREE
Barclays recently hosted a meeting with Coach's (NYSE: COH) management.
Analyst, Robert S. Drbul's three highlights points are: 1) The company continues to believe that the men's business presents a $1-billion opportunity in the next 3-5 years; 2) Coach's new Legacy line, due in August 2012, is likely to further differentiate the brand from its nearest competitors; and 3) Traffic across all channels is up substantially including online which is the company's fastest growing channel, yet down in full price stores.
Barclays maintains an 'Overweight' on Coach (COH) and raised its price
target from $76 to $82.
Shares of COH are currently trading up 0.54% to $72.96.
For an analyst ratings summary and ratings history on Coach click here. For more ratings news on Coach click here.
Shares of Coach closed at $72.57 yesterday.
Analyst, Robert S. Drbul's three highlights points are: 1) The company continues to believe that the men's business presents a $1-billion opportunity in the next 3-5 years; 2) Coach's new Legacy line, due in August 2012, is likely to further differentiate the brand from its nearest competitors; and 3) Traffic across all channels is up substantially including online which is the company's fastest growing channel, yet down in full price stores.
Barclays maintains an 'Overweight' on Coach (COH) and raised its price
target from $76 to $82.
Shares of COH are currently trading up 0.54% to $72.96.
For an analyst ratings summary and ratings history on Coach click here. For more ratings news on Coach click here.
Shares of Coach closed at $72.57 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Marvell (MRVL) PT Raised to $225 at TD Cowen
- Amylyx Pharmaceuticals inc. (AMLX) PT Raised to $55 at H.C. Wainwright
- Outlook Therapeutics Inc. (OTLK) PT Lowered to $4 at Brookline Capital Markets
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
